Advertisement

Childhood- Versus Adult-Onset Primary Vasculitides: Are They Part of the Same Clinical Spectrum?

  • Renato Ferrandiz-EspadinEmail author
  • Manuel Ferrandiz-Zavaler
Vasculitis (L Espinoza, Section Editor)
  • 95 Downloads
Part of the following topical collections:
  1. Topical Collection on Vasculitis

Abstract

Purpose of the Review

Most of the primary vasculitis in children and adults has different clinical manifestations for the same disease, which suggests that they might not be part of the same clinical spectrum and requires a different approach in order to reduce the morbidity and mortality of these patients. In this work, we review the most recent literature and the most important studies that describe and compare adult and children primary vasculitides pathogenesis, clinical presentation, and treatment approach. Accordingly, we discuss recent research involving clinical trials, comparison studies, and pathogeny for these vasculitides.

Recent Findings

Clinical manifestations in the different primary vasculitis change in predominance from adults to children. There is a female sex predominance for the ANCA vasculitides in children compared with adults, but the same treatment works in most cases for both groups.

Summary

Identifying the diverse clinical spectrum in both adults and children primary vasculitides will reduce the need to extrapolate the diagnostic criteria from one group to another and individualize it, which will allow the clinician to establish a better approach.

Keywords

Systemic vasculitis Pathogenesis Pediatric vasculitides Primary vasculitides Treatment 

Notes

Compliance with Ethical Standards

Conflict of Interest

The authors of this work do not have conflict of interest to disclose.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Ozen S, Onmez HE, Demir S. Pediatric forms of vasculitis. Best Pract Res Clin Rheumatol. 2018;32:137–47.  https://doi.org/10.1016/j.berh.2018.09.007.CrossRefPubMedGoogle Scholar
  2. 2.
    Jennette JC. Overview of the 2012 revised international Chapel Hill consensus conference nomenclature of vasculitides. Clin Exp Nephrol. 2013;17:603–6.  https://doi.org/10.1007/s10157-013-0869-6.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Demir S et al. Vasculitis: decade in review. Current Rheumatology Reviews, 2018, 14, 00–00. This study Doi:  https://doi.org/10.2174/1573397114666180726093731, Vasculitis: Decade in Review.CrossRefGoogle Scholar
  4. 4.
    Sag E, et al. Childhood systemic vasculitis. Best practice & research clinical rheumatology. 2017;31(4):558–75.  https://doi.org/10.1016/j.berh.2017.11.009.CrossRefGoogle Scholar
  5. 5.
    Moran S, et al. IgA vasculitis in adults. Curr Treat Options in Rheum. 2018;4:119–32.  https://doi.org/10.1007/s40674-018-0088-0.CrossRefGoogle Scholar
  6. 6.
    Journeau L, Pistorius MA, et al. Juvenile temporal arteritis: a clinicopathological multicentric experience. Autoimmun Rev. 2019;18(5):476–83.  https://doi.org/10.1016/j.autrev.2019.03.007.CrossRefPubMedGoogle Scholar
  7. 7.
    Di Santo M, Stelmaszewski EV, Villa A. Takayasu arteritis in paediatrics. Cardiol Young. 2018;28:354–61.  https://doi.org/10.1017/S1047951117001998.CrossRefPubMedGoogle Scholar
  8. 8.••
    Panupattanapong S. Epidemiology and outcomes of granulomatosis with polyangiitis in pediatric and working-age adult populations in the United States: analysis of a large National Claims Database. Arthritis Rheumatol. 2018;70(12):2067–76.  https://doi.org/10.1002/art.40577. This is one of the biggest and most descriptive works about GPA.CrossRefPubMedGoogle Scholar
  9. 9.•
    Watts R. Evolving concepts in classification of systemic vasculitis: where are we and what is the way forward? International Journal of Rheumatic Diseases 2018. 22 Suppl 1:21–27. This article discusses the current classification and the future of it. doi:  https://doi.org/10.1111/1756-185X.13304.CrossRefGoogle Scholar
  10. 10.
    Johnston SL, Lock RJ, Gompels MM. Takayasu arteritis: a review. J Clin Pathol. 2002;55:481–6.  https://doi.org/10.1136/jcp.55.7.481.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.••
    Mathew AJ, et al. Childhood-onset Takayasu arteritis: an update. International Journal of Rheumatic Diseases. 2016;19:116–26. This article describes the epidemiology and the biggest works on childhood Takayasu Vasculitis.  https://doi.org/10.1111/1756-185X.12718.CrossRefPubMedGoogle Scholar
  12. 12.
    Eleftheriou D, et al. Takayasu arteritis in childhood: retrospective experience from a tertiary referral centre in the United Kingdom. Arthritis Research & Therapy. 2015:17–36.  https://doi.org/10.1186/s13075-015-0545-1.
  13. 13.
    Aeschlimann FA, Eng SWM, Sheikh S, Laxer RM, Hebert D, Noone D, et al. Diagnosis, treatment, and long-term management of Kawasaki disease a Statement for health professionals from the committee on rheumatic fever, endocarditis and Kawasaki disease, council on cardiovascular disease in the young, American Heart Association endorsed by the American Academy of Pediatrics Childhood Takayasu arteritis: disease course and response to therapy. Circulation. 2017;19:255.  https://doi.org/10.1186/s13075-017-1452-4.
  14. 14.
    Newburger JW, Takahashi M., Gerber MA, Gewitz MH, Tani LY, Burns JC, Shulman ST, Bolger AF, Ferrieri P, Baltimore RS, Wilson WR, Baddour LM, Levison ME, Pallasch TJ, Falace DA, Taubert KA, Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease., Council on Cardiovascular Disease in the Young., American Heart Association., American Academy of Pediatrics. . 2004;110:2747–71. Doi: https://doi.org/10.1161/01.CIR.0000145143.19711.78.CrossRefGoogle Scholar
  15. 15.
    Uehara R. Recent topics in the Epidemiology of Kawasaki disease. In: Tsutomu-Saji B, Newburger JW, Burns JC, Takahashi M, editors. Kawasaki Disease: Current Understanding of the Mechanism and Evidence-Based Treatment. Springer; 2017. 91–94.Google Scholar
  16. 16.
    Tai-Lin M, Wu MH. The global epidemiology of Kawasaki disease: review and future perspectives. Global Cardiology Science and Practice 2017:20. Doi:  https://doi.org/10.21542/gcsp.2017.20
  17. 17.
    Newburger JW, Takahashi M, Burns JC. Kawasaki Disease Journal of the American College of Cardiology. 2016;67(14).  https://doi.org/10.1016/j.jacc.2015.12.073.CrossRefGoogle Scholar
  18. 18.
    Mossberg M, Segelmark M, Kahn R, Englund M, Mohammad AJ. Epidemiology of primary systemic vasculitis in children: a population-based study from southern Sweden. Scand J Rheumatol. 2018;47(4):295–302.  https://doi.org/10.1080/03009742.2017.1412497.CrossRefPubMedGoogle Scholar
  19. 19.•
    Fraison JB, et al. Kawasaki disease in adults: observations in France and literature review. Autoimmun Rev. 2016;(3):242–9. This article has a extended description and revision of adult Kawasaki.  https://doi.org/10.1016/j.autrev.2015.11.010.CrossRefGoogle Scholar
  20. 20.
    Burns JC, Kushner HI, Bastian JF, Shike H, Shimizu C, Matsubara T, et al. Kawasaki disease: a brief history. Pediatrics. 2000;106(2):E27.  https://doi.org/10.1542/peds.106.2.e27.CrossRefGoogle Scholar
  21. 21.
    Denby KJ, Clark DE, Markham LW Management of Kawasaki disease in adults. Heart. 2017 0:1–9. Doi:  https://doi.org/10.1136/heartjnl-2017-311774, 103.CrossRefGoogle Scholar
  22. 22.
    Guillevin L. Polyarteritis Nodosa. In Nussinovitch U, editor. The heart in rheumatic, autoimmune and inflammatory diseases pathophysiology, clinical aspects and therapeutic approaches. Elsevier. 2017. Chapter 18: 419–427.Google Scholar
  23. 23.
    Sönmez H, et al. Polyarteritis nodosa: lessons from 25 years of experience. Clin Exp Rheumatol. 2019;37(Suppl. 117):S52–6.Google Scholar
  24. 24.
    Jayne DJ, Karadag O. Polyarteritis nodosa revisited: a review of historical approaches, subphenotypes and a research agenda. Clin Exp Rheumatol 2018. s135-s142.Google Scholar
  25. 25.
    Ozen S. The changing face of polyarteritis nodosa and necrotizing vasculitis. Nat Rev Rheumatol. 2017;13(6):381–6.  https://doi.org/10.1038/nrrheum.2017.68.CrossRefPubMedGoogle Scholar
  26. 26.
    Pagnoux C, Seror R, Henegar C, Mahr A, Cohen P, le Guern V, et al. Clinical features and outcomes in 348 patients with polyarteritis nodosa a systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French Vasculitis study group database. Arthritis & Rheumatism. 2010;62(2):616–26.  https://doi.org/10.1002/art.27240.CrossRefGoogle Scholar
  27. 27.
    Ozen S. Juvenile polyarteritis: results of a multicenter survey of 110 children. J Pediatr. 2004;145:517–22.  https://doi.org/10.1016/j.jpeds.2004.06.046.CrossRefPubMedGoogle Scholar
  28. 28.
    De Virgilio A, et al. Polyarteritis nodosa: a contemporary overview. Autoimmunity Reviews. 15(6):564–70.  https://doi.org/10.1016/j.autrev.2016.02.015.CrossRefGoogle Scholar
  29. 29.
    Erden A. Comparing polyarteritis nodosa in children and adults: a single center study. Int J Rheum Dis. 2017;20(8):1016–22.  https://doi.org/10.1111/1756-185X.13120.CrossRefPubMedGoogle Scholar
  30. 30.
    Mahr A, de Menthon M. Classification and classification criteria for vasculitis. Curr Opin Rheumatol. 2015;27(1):1–9.  https://doi.org/10.1097/bor.0000000000000134.CrossRefPubMedGoogle Scholar
  31. 31.
    Lahiry S, et al. Childhood polyarteritis nodosa: a rare presentation. Asian Journal of Medical Sciences. 2016;7(6).  https://doi.org/10.3126/ajms.v7i6.15724.CrossRefGoogle Scholar
  32. 32.••
    Iudici M. Childhood- versus adult-onset polyarteritis nodosa results from the French Vasculitis Study Group Registry. Autoimmunity Reviews. 2018;17:984–9.  https://doi.org/10.1016/j.autrev.2018.08.001. This article is the biggest study that compares adult and child PAN.CrossRefPubMedGoogle Scholar
  33. 33.
    Barut K, Sahin S, Kasapcopur O. Pediatric vasculitis. Curr Opin Rheumatol. 2016;28:29–38.  https://doi.org/10.1097/BOR.0000000000000236.CrossRefPubMedGoogle Scholar
  34. 34.
    Cabral DA, Morishita K. Granulomatosis with polyangiitis in children. In S. Sawhney, editor. Pediatric rheumatology: a clinical viewpoint. Springer. 2017. Chapter 36:461–479.Google Scholar
  35. 35.
    Bingham D, et al. A10: younger age and severity of renal presentation distinguishes microscopic polyangiitis from granulomatosis with polyangiitis in children: an ARChiVe study. Arthritis & Rheumatology. 2014;66(S3):S15–6.  https://doi.org/10.1002/art.38421.CrossRefGoogle Scholar
  36. 36.
    Piram M, Mahr A. Epidemiology of immunoglobulin a vasculitis(Henoch–Schonlein): current state of knowledge. Curr Opin Rheumatol. 2013;25:171–8.  https://doi.org/10.1097/BOR.0b013e32835d8e2a.CrossRefPubMedGoogle Scholar
  37. 37.
    Piram M, Maldini C. Incidence of IgA vasculitis in children estimated by four-source capture_recapture analysis: a population-based study. Rheumatology. 2017;56(8):1358–66.  https://doi.org/10.1093/rheumatology/kex158.CrossRefPubMedGoogle Scholar
  38. 38.
    Chen JY, Mao JH. Henoch-Schönlein purpura nephritis in children: incidence, pathogenesis and management. World J Pediatr. 2015;11(1):29–34.  https://doi.org/10.1007/s12519-014-0534-5.CrossRefPubMedGoogle Scholar
  39. 39.
    Tracy A, Subramanian A, Adderley NJ, et al. Cardiovascular, thromboembolic and renal outcomes in IgA vasculitis (Henoch-Schönlein purpura): a retrospective cohort study using routinely collected primary care data. Ann Rheum Dis. 2019;78:261–9.  https://doi.org/10.1136/annrheumdis-2018-214142.CrossRefPubMedGoogle Scholar
  40. 40.
    Hocevar A, Rotar Z, Jurcic V. IgA vasculitis in adults: the performance of the EULAR/PRINTO/PRES classification criteria in adults. Arthritis Res Ther. 2016;18:58.  https://doi.org/10.1186/s13075-016-0959-4.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Yao-Hsu Y, Hsin-hui Y. The diagnosis and classification of Henoch–Schönlein purpura: an updated review. Autoimmunity Reviews. 2014;13(4–5):355–8.  https://doi.org/10.1016/j.autrev.2014.01.031.CrossRefGoogle Scholar
  42. 42.
    EULAR/PRINTO/PRES criteria for Henoch–Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria. Ann Rheum Dis 2010;69:798–806. doi: 10.1136/ard.2009.116657.CrossRefGoogle Scholar
  43. 43.
    Gupta V, Aggarwal A, Gupta R. Differences between adult and pediatric onset. Henoch-Schonlein purpura from North India. Int J Rheum Dis. 2018;21:292–8.  https://doi.org/10.1111/1756-185X.13221.CrossRefPubMedGoogle Scholar
  44. 44.
    Vogler C, Eliason SC, Wood EG. Glomerular membranopathy in children with IgA nephropathy and Henoch Schonlein Purpura. Pediatr Dev Pathol. 1999;2:227–35.CrossRefGoogle Scholar
  45. 45.
    Brogan P, Eleftheriou D. Vasculitis update: pathogenesis and biomarkers. Pediatr Nephrol. 2018;33(2):187–98.  https://doi.org/10.1007/s00467-017-3597-4.CrossRefPubMedGoogle Scholar
  46. 46.
    Pertuiset E. Liotd F. et al. Adult Henoch-SchSnlein purpura associated with malignancy. Seminars in arthritis and rheumatism. 2000. Vo1 29, 6: 360–367.Google Scholar
  47. 47.
    Ostrovršnik J, Rotar &, Ješe R, et al THU0448 Is there an association between adult iga vasculitis and cancer? Ann Rheum Dis 2018;77:436.  https://doi.org/10.1136/annrheumdis-2018-eular.5359
  48. 48.
    Batu E, et al. Comparing immunoglobulin a vasculitis (Henoch–Schönlein purpura) in children and adults: a single-centre study from Turkey. Scand J Rheumatol. 2018:1–6.  https://doi.org/10.1080/03009742.2018.144811150.
  49. 49.
    Audemard-Verger A, Terrier B, et al. Characteristics and management of IgA vasculitis (Henoch-Schonlein) in Adults. Arthritis & Rheumatology. 2017;69(9):1862–70.  https://doi.org/10.1002/art.40178.CrossRefGoogle Scholar
  50. 50.
    Selewski DT, Ambruzs JM, et al. Clinical characteristics and treatment patterns of children and adults with IgA nephropathy or IgA vasculitis: Findings from the CureGN study. Kidney Int Rep. 2018;3(6):1373–84.  https://doi.org/10.1016/j.ekir.2018.07.021.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Gibson K, Glenn D. ANCA-associated vasculitis, Pediatric. In Gibson, Keisha & Glenn, Dorey, editor. Glomerulonephritis. 2019. Chapter 17: 419–427. Doi:  https://doi.org/10.1007/978-3-319-49379-4_18 CrossRefGoogle Scholar
  52. 52.
    Cabral DA, et al. Comparing presenting clinical features in 48 children with microscopic polyangiitis to 183 children who have granulomatosis with polyangiitis (Wegener’s): an ARChiVe cohort study. Arthritis & Rheumatology. 2016;68(10):2514–26.  https://doi.org/10.1002/art.39729.CrossRefGoogle Scholar
  53. 53.
    Ball GV. The history of ANCA associated vasculitis. Rheum Dis Clin N Am. 2010;36:439–46.  https://doi.org/10.1016/j.rdc.2010.05.004.CrossRefGoogle Scholar
  54. 54.
    Jariwala MP, Laxer RM. Primary vasculitis in childhood: GPA and MPA in childhood. Front Pediatr. 2018;6:226.  https://doi.org/10.3389/fped.2018.00226.CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Plumb LA, Oni L, Marks SD, Tullus K. Paediatric anti-neutrophil cytoplasmic antibody (ANCA) -associated vasculitis: an update on renal management. Pediatr Nephrol. 2018;33:25–39.CrossRefGoogle Scholar
  56. 56.
    Ozen S, Acar-Ozen NP. Recent advances in childhood vasculitis. Curr Opin Rheumatol 2017. 29:000–000. doi:  https://doi.org/10.1097/BOR.0000000000000424, 534.CrossRefGoogle Scholar
  57. 57.
    Berti A, Cornec D, Crowson CS, Specks U, Matteson EL. The epidemiology of ANCA associated vasculitis in Olmsted County, Minnesota (USA): a 20 year population-based study. Arthritis Rheumatol. 2017 Dec;69(12):2338–50.  https://doi.org/10.1002/art.40313.CrossRefPubMedPubMedCentralGoogle Scholar
  58. 58.••
    Iudici M, et al. Childhood- versus adult-onset ANCA-associated vasculitides: a nested, matched case-control study from the French Vasculitis Study Group Registry. Autoimmun Rev. 2018;17(2):108–14.  https://doi.org/10.1016/j.autrev.2017.11.014. The French vasculitis group has described extensively ANCA vasculitis in children and adults.CrossRefPubMedGoogle Scholar
  59. 59.
    Noone D, Hebert D, Licht C. Pathogenesis and treatment of ANCA-associated vasculitis—a role for complement. Pediatr Nephrology. 2018;33(1):1–11.  https://doi.org/10.1007/s00467-016-3475-5.CrossRefGoogle Scholar
  60. 60.
    Morishita KA. Early outcomes in children with Antineutrophil cytoplasmic antibody-associated Vasculitis. Arthritis Rheumatol. 2017;69(7):1470–9.  https://doi.org/10.1002/art.40112.CrossRefPubMedGoogle Scholar
  61. 61.
    Iudici M, Quartier P, Terrier B, Mouthon L, Guillevin L, Puéchal X. Childhood-onset granulomatosis with polyangiitis and microscopic polyangiitis: systematic review and meta-analysis. Orphanet Journal of Rare Diseases. 2016;11:141.  https://doi.org/10.1186/s13023-016-0523-y.CrossRefPubMedPubMedCentralGoogle Scholar
  62. 62.
    James KE, Xiao R, Merkel PA, Weiss PF. Variation in the treatment of children hospitalized with Antineutrophil cytoplasmic antibody-associated Vasculitis in the US. Arthritis Care Res (Hoboken). 2017;69(9):1377–83.  https://doi.org/10.1002/acr.23142.CrossRefGoogle Scholar
  63. 63.
    Comarmond C. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group Cohort. Arthritis & Rheumatism. 2013;65(1):270–81.  https://doi.org/10.1002/art.37721.CrossRefGoogle Scholar
  64. 64.
    Sada KE, Amano K, Uehara R, Yamamura M, Arimura Y, Nakamura Y, et al. Mod Rheumatol. 2014;24(4):640–4.  https://doi.org/10.3109/14397595.2013.857582.CrossRefGoogle Scholar
  65. 65.
    Fina A, Dubus JC, Tran A, Derelle J, Reix P, Fayon M, et al. Eosinophilic granulomatosis with polyangiitis in children: data from the French RespiRare® cohort. Pediatr Pulmonol. 2018;53:1–11.  https://doi.org/10.1002/ppul.24089.CrossRefGoogle Scholar
  66. 66.
    Zwerina J. Churg–Strauss syndrome in childhood: a systematic literature review and clinical comparison with adult patients. Semin Arthritis Rheum. 2009;39(2):108–15.  https://doi.org/10.1016/j.semarthrit.2008.05.004.CrossRefPubMedGoogle Scholar
  67. 67.
    Wu EY. Eosinophilic granulomatosis with polyangiitis: clinical pathology conference and review. The Journal of Allergy and Clinical Immunology: In Practice. 2018;6(5):1496–504.  https://doi.org/10.1016/j.jaip.2018.07.001.CrossRefPubMedGoogle Scholar
  68. 68.
    Alba MA, Jennette J, Falk R. Pathogenesis of ANCA-associated pulmonary vasculitis. Semin Respir Crit Care Med. 2018;39:413–24.  https://doi.org/10.1055/s-0038-1673386.CrossRefPubMedPubMedCentralGoogle Scholar
  69. 69.
    Dumoitier N, Terrier B, London J, Lofek S, Mouthon L. Implication of B lymphocytes in the pathogenesis of ANCA-associated vasculitides. Autoimmun Rev. 2015;14(11):996–1004.CrossRefGoogle Scholar
  70. 70.
    Hanna L, V G. Presentation and classification of rare primary vasculitides in children. Journal of Vasculitis. 2016;2:2.  https://doi.org/10.4172/2471-9544.100107.CrossRefGoogle Scholar
  71. 71.
    Karras A. Microscopic polyangiitis: new insights into pathogenesis, clinical features and therapy. Semin Respir Crit Care Med. 2018;39:459–64.  https://doi.org/10.1055/s-0038-1673387.CrossRefPubMedGoogle Scholar
  72. 72.
    Dammacco F, Vacca A. Microscopic Polyangiitis in Dammacco, F., Ribatti, D., & Vacca, A. (Eds.). Systemic vasculitides: current status and perspectives. 2016. Chapter 10: 109–118.Google Scholar
  73. 73.
    Wang H, Sun L, Tan W. Clinical features of children with pulmonary microscopic polyangiitis: report of 9 cases. PLoS One. 2015;10(4):e0124352.  https://doi.org/10.1371/journal.pone.0124352.CrossRefPubMedPubMedCentralGoogle Scholar
  74. 74.
    Schirmer JH. Clinical presentation and long-term outcome of 144 patients with microscopic polyangiitis in a monocentric German cohort. Rheumatology (Oxford). 2016;55(1):71–9.  https://doi.org/10.1093/rheumatology/kev286.CrossRefGoogle Scholar
  75. 75.
    Microscopic polyangiitis: from pathogenesis to treatment. Urol Nephrol Open Access J 2017, 5(2): 00167. Doi:  https://doi.org/10.15406/unoaj.2017.05.00167
  76. 76.
    Pagnoux C. Updates in ANCA-associated vasculitis. Eur J Rheumatol. 2016;3(3):122–33.CrossRefGoogle Scholar
  77. 77.
    et al. Lythgoe H, Presentation and classification of rare primary vasculitides in children. J Vasc. 2016;2:2.  https://doi.org/10.4172/2471-9544.100107.
  78. 78.
    Jarrot PA, Kaplanski G. Pathogenesis of ANCA-associated vasculitis: an update. Autoimmun Rev. 2016;15(7):704–13.  https://doi.org/10.1016/j.autrev.2016.03.007.CrossRefPubMedGoogle Scholar
  79. 79.
    Nakano N, Mori M, Umebayashi H, Iwata N, Kobayashi N, Masunaga K, et al. Characteristics and outcome of intractable vasculitis syndrome in children: nation-wide survey in Japan. Mod Rheumatol. 2017;28:1439–7595.  https://doi.org/10.1080/14397595.2017.1404700.CrossRefGoogle Scholar
  80. 80.
    Schnabel A, Hedrich CM. Childhood vasculitis. Front. Pediatr. 2019;6:421.  https://doi.org/10.3389/fped.2018.00421.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Renato Ferrandiz-Espadin
    • 1
    Email author
  • Manuel Ferrandiz-Zavaler
    • 2
  1. 1.Universidad Peruana Cayetano HerediaLimaPeru
  2. 2.Department of RheumatologyInstituto Nacional de Salud del NiñoLimaPeru

Personalised recommendations